AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01494636
Drug: GSK2339345 (nebulised)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25, 100, 250, 1000 and 2000 micrograms (proposed doses). Subjects randomised to receive three ascending doses (with each dose given on two consecutive days). Washout of at least 6 days between treatment periods. Nebulised.
Trial: NCT00555724
Drug: BIIB022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion once every three weeks until disease progression or unacceptable toxicity
Trial: NCT01094210
Drug: Fluorides, Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.
Trial: NCT02648490
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.
Trial: NCT02981979
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: used in control group during the induced remission therapy for 24 weeks.
Trial: NCT03040401
Drug: Cohort 1, Ceplene® and Proleukin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Cohort 1 will be administered only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2.
Trial: NCT03040401
Drug: Cohort 2, Ceplene® and Proleukin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Cohort 2 will be administered Ceplene® in combination with Proleukin® during all treatment cycles 1-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2.
Trial: NCT03040401
Drug: Cohort 3, Ceplene® and Proleukin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2.
Trial: NCT00143338
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00593294
Drug: OC - Drospirenone plus Ethynylestradiol
RxNorm normalized name: drospirenone and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
Trial: NCT03407937
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo is a substance (or treatment) with no active therapeutic effect. The placebo effect (analgesia) in this study will be induced by the oral administration of one inert tablet (sugar pill). The tablet is a round, hard, white, flat-faced tablet with no active ingredient. The participant is told that the tablet is an active drug, more specifically an analgesic or a painkiller, that is used to achieve analgesia, relief from pain. This placebo condition is used to induce a diffuse analgesic effect in participants.
Trial: NCT02664142
Drug: Anaesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
Trial: NCT03720678
Drug: mFOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen
Trial: NCT03054428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
Trial: NCT02877238
Drug: Total intravenous anesthesia plus remote ischemic preconditioning
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
Trial: NCT04356937
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)
Trial: NCT01265498
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule, 25 mg daily for 72 weeks
Trial: NCT00061984
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00884520
Drug: [F-18] VM4-037
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The individual doses of \[F-18\]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging.
Trial: NCT02932566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
Trial: NCT02516332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03092752
Drug: oral antidiabetic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OADs usage conditions and dose selection in T2DM patients
Trial: NCT03706261
Drug: 18F-MK-6240
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 5 mCi of 18F-MK-6240 for tau PET.
Trial: NCT04383730
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be included retrospectively in the study by local investigators at each participating center. As this is a non-interventional study, sedation practices will be those currently used as standard practices in participating centers, including both intravenous and inhaled sedation practices
Trial: NCT00987636
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.~Patients \< 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.~Patients \>= 18 years will receive a bodyweight-dependent dose:~Patients \>40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h
Trial: NCT00471484
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00471484
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00709332
Drug: Norgestimate; Ethinyl Estradiol; Folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01951508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per os
Trial: NCT03533751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT02791867
Drug: AphoelineBrake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
Trial: NCT00223704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
Trial: NCT02028598
Drug: Treatment 1
RxNorm normalized name: CVS Acne Treatment 10% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral single dose administration
Trial: NCT02028598
Drug: Treatment 2
RxNorm normalized name: epoch Blemish Treatment 2 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral single dose administration
Trial: NCT00419536
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05418803
Drug: YHP1807 Tab. 2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5mg
Trial: NCT05418803
Drug: YHR1901 Tab. 2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5mg
Trial: NCT01591161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop of vehicle into the study eye QID for 14 days.
Trial: NCT02540928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03620513
Drug: Anesthesia (Lidocaine 15%)
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As described in arm/group
Trial: NCT03620513
Drug: Decongestants and Anesthesia (oxymetazoline and lidocaine)
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As described in arm/group
Trial: NCT03620513
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray of normal saline as premedication
Trial: NCT01553773
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
Trial: NCT04481139
Drug: SHR0302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302, oral, once daily
Trial: NCT04481139
Drug: SHR0302 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302 placebo, oral, once daily
Trial: NCT04650737
Drug: single shot ESBP with dexmedtomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine
Trial: NCT04650737
Drug: continous ESPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive erector spine plane block with 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs.
Trial: NCT00103285
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00103285
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or IT
Trial: NCT00103285
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00103285
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00103285
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IM or IT
Trial: NCT01278758
Drug: ASA404, DMXAA or DXAA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00041548
Drug: nitric oxide for inhalation
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given at 20 ppm for 1 hour then weaned off over 4 hours
Trial: NCT00150176
Drug: Placebo - Double Blind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
Trial: NCT02169219
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.~Prednisone will be tapered over 8 weeks as follows:~* 60mg for 2 weeks~* 40mg for 2 weeks~* 30mg for 1 week~* 20mg for 1 week~* 10mg for 1 week~* 5mg for 1 week
Trial: NCT00689585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg matching placebo capsules
Trial: NCT03220841
Drug: Thiopurine
RxNorm normalized name: Thiopurine methyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose optimized thiopurine
Trial: NCT01386606
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical gel~1X a day 6 weeks
Trial: NCT02176213
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low dose cyclophosphamide 50 mg PO BID x 21 days
Trial: NCT00398125
Drug: GSK364735
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04472819
Drug: SHR2285 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose or multi-dose
Trial: NCT04472819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose or multi-dose
Trial: NCT04371185
Drug: BAT2206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
Trial: NCT01764685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03646591
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive four cycles of the standard dose of FLOT chemotherapy prior to curative gastrectomy. And four cycles of the FLOT chemotherapy is recommended after surgery. Preventive antiemetic and dexamethasone are allowed before chemotherapy, growth factor, or other supportive medicines are allowed for treatment only. Surgical intervention is allowed for acute bleeding or other surgical emergencies.
Trial: NCT01015339
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
Trial: NCT04591639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
Trial: NCT02233543
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivered once daily via single-dose dry powder inhaler
Trial: NCT01046864
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
Trial: NCT01488877
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: spironolactone 25 mg once daily
Trial: NCT01095172
Drug: Mycophenylate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenylate mofetil 2g/day in divided doses
Trial: NCT01095172
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
Trial: NCT01095172
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.
Trial: NCT01095172
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
Trial: NCT03163446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given as a single 2 hour iv infusion
Trial: NCT00704379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an inactive substance
Trial: NCT00002551
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See arm assignments.
Trial: NCT00002551
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See arm assignments.
Trial: NCT02490774
Drug: BAY1007626
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)
Trial: NCT03652818
Drug: Pre-Op Placebo 1
RxNorm normalized name: Sx Pre-Op Prep Pouch KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 will be administered 60 min prior to surgery.
Trial: NCT03652818
Drug: Post-Op Placebo 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 will be administered post-operatively.
Trial: NCT03652818
Drug: Post-Op Placebo 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 will be administered post-operatively.
Trial: NCT03652818
Drug: Post-Op acetaminophen
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen will be administered Post-operatively.
Trial: NCT03186313
Drug: Dactavira Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
Trial: NCT03186313
Drug: Dactavira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks
Trial: NCT00524433
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00830219
Drug: Requip® 0.25 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 0.25 mg, single dose fed
Trial: NCT01533870
Drug: NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 25 mg
Trial: NCT04129697
Drug: Dexamethasone or Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: steroids
Trial: NCT01940224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative administration of placebo
Trial: NCT01052103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
Trial: NCT01052103
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
Trial: NCT00184665
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01174732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, lactose inhalation carrier
Trial: NCT00766363
Drug: EVP-6124 (0.1 mg/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.
Trial: NCT00766363
Drug: EVP-6124 (0.3 mg/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.
Trial: NCT00766363
Drug: EVP-6124 (1.0 mg/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.
Trial: NCT00469573
Drug: 1. Optive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optive 15ml- (in the eye) Instill one drop twice daily in each eye
Trial: NCT01912560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01912560
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.
Trial: NCT00094289
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02238808
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.
Trial: NCT00239720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose of placebo given over 5 days of each 28 day cycle
Trial: NCT02687854
Drug: Vitamin K antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed by treating physicians
Trial: NCT04339049
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement